LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

Search

Arcus Biosciences Inc

Abierto

SectorSanidad

8.53 -2.51

Resumen

Variación precio

24h

Actual

Mínimo

8.5

Máximo

8.85

Métricas clave

By Trading Economics

Ingresos

-18M

-112M

Ventas

2M

28M

BPA

-1.14

Margen de beneficios

-400

Empleados

627

EBITDA

-34M

-122M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+190.69% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

13M

978M

Apertura anterior

11.04

Cierre anterior

8.53

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

170 / 381 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Arcus Biosciences Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 jun 2025, 17:32 UTC

Principales Movimientos del Mercado

Lion Group Shares Climb on $600 Million Loan for Crypto Treasury

18 jun 2025, 23:55 UTC

Adquisiciones, fusiones, absorciones

Nippon Steel: To Book Restructuring Loss Related to This Sale in 1Q

18 jun 2025, 23:53 UTC

Adquisiciones, fusiones, absorciones

Nippon Steel: NS Kote Is an Entity That Owns All of Company's Equity Stake in AM/NS Calvert

18 jun 2025, 23:50 UTC

Adquisiciones, fusiones, absorciones

Nippon Steel: To Book About Y230B Loss Related to Sale of NS Kote to ArcelorMittal

18 jun 2025, 23:50 UTC

Charlas de Mercado

Australian Uranium Stocks Tipped to Go Higher -- Market Talk

18 jun 2025, 23:43 UTC

Charlas de Mercado

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

18 jun 2025, 23:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

18 jun 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

18 jun 2025, 23:07 UTC

Charlas de Mercado

Fletcher Building Recovery May Be More Muted Than Thought -- Market Talk

18 jun 2025, 23:00 UTC

Charlas de Mercado

Smart Glasses Seen as Possible Future Agentic AI Platform -- Market Talk

18 jun 2025, 21:50 UTC

Charlas de Mercado

Argentina Poised To Become Significant LNG Exporter, Rystad Says -- Market Talk

18 jun 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

18 jun 2025, 20:38 UTC

Adquisiciones, fusiones, absorciones

U.S. Steel and Nippon Finalize Their 'Partnership.' What Comes After the Merger. -- Barrons.com

18 jun 2025, 20:32 UTC

Ganancias

These Stocks Moved the Most Today: Tesla, Marvell, Sunrun, Nucor, Circle Internet, Korn Ferry, GMS, and More -- Barrons.com

18 jun 2025, 19:59 UTC

Charlas de Mercado

Oil Edges Up as Next Steps in Iran Conflict Eyed -- Market Talk

18 jun 2025, 19:42 UTC

Charlas de Mercado

Natural Gas Extends Gains for Fourth Session -- Market Talk

18 jun 2025, 19:40 UTC

Ganancias

Fed Holds Rates Steady and Keeps Door Open to Cuts -- 3rd Update

18 jun 2025, 18:47 UTC

Adquisiciones, fusiones, absorciones

Railroads Have Slashed Costs and Raised Prices. Why One CEO Now Favors a Merger. -- Barrons.com

18 jun 2025, 18:33 UTC

Charlas de Mercado

Fitch Says U.S. Fiscal Outlook Remains Challenging -- Market Talk

18 jun 2025, 18:26 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

18 jun 2025, 18:26 UTC

Charlas de Mercado

Nucor, Steel Dynamics Seen Diverging In Approach To Current Business Climate -- Market Talk

18 jun 2025, 18:15 UTC

Charlas de Mercado

Gold Stays Flat After Fed Decision -- Market Talk

18 jun 2025, 17:42 UTC

Adquisiciones, fusiones, absorciones

ArcelorMittal Expects Related 2Q Gain of About $1.5B

18 jun 2025, 17:40 UTC

Adquisiciones, fusiones, absorciones

ArcelorMittal Completes Acquisition of Nippon Steel's 50% Interest in AM/NS Calvert

18 jun 2025, 17:20 UTC

Ganancias

Credit Card Annual Fees Are Going Up. What It Means for the Stocks. -- Barrons.com

18 jun 2025, 16:52 UTC

Charlas de Mercado

Trump Awakens Canada On Need For Fewer Trade Barriers, Macklem Says -- Market Talk

18 jun 2025, 16:31 UTC

Adquisiciones, fusiones, absorciones

Nippon Steel Completes Purchase of U.S. Steel After Reaching Security Deal With Trump Administration -- Update

18 jun 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

18 jun 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

18 jun 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Arcus Biosciences Inc previsión

Precio Objetivo

By TipRanks

190.69% repunte

Estimación a 12 Meses

Media 25.29 USD  190.69%

Máximo 46 USD

Mínimo 12 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arcus Biosciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

8

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

8.01 / 8.75Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Neutral Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

170 / 381 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.